SCHEMBL753579

SCHEMBL753579

CCOc1cc([C@@H](N)CS(C)(=O)=O)ccc1OC

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 20/20 0.59
PDE4A P27815 9/20 0.59
PDE4C Q08493 9/20 0.59
PDE4D Q08499 9/20 0.59
HTR2B P41595 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL636037 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL15580926 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL302947 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL15869339 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL15869362 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL15580915 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL29679711 1.00 PDE4B (0.59) PDE4BPDE4APDE4CPDE4DHTR2B
SCHEMBL752748 0.94 PDE4B (0.53) PDE4BPDE4APDE4CPDE4D
SCHEMBL16572255 0.91 PDE4B (0.50) PDE4BPDE4APDE4CPDE4D
SCHEMBL706429 0.91 PDE4B (0.50) PDE4BPDE4APDE4CPDE4DHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118047701-A Preparation method of apremilast intermediate 浙江华义制药有限公司 2024-05-17 CN claimed
CN-110627694-B Method for recovering 3-ethoxy-4-methoxy-alpha- [ (methylsulfonyl) methyl ] -benzylamine 山东邹平大展新材料有限公司 2021-06-15 CN claimed
CN-107860844-B Method for detecting (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine 中山奕安泰医药科技有限公司 2020-07-07 CN claimed
CN-110627694-A Method for recovering 3-ethoxy-4-methoxy-alpha- [ (methylsulfonyl) methyl ] -benzylamine 山东邹平大展新材料有限公司 2019-12-31 CN claimed
US-20180334429-A1 PROCESS FOR PREPARATION OF APREMILAST AND ITS INTERMEDIATES Dr Reddys Laboratories Ltd (IN) 2018-11-22 US claimed
EP-3619195-B1 NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE UNICHEM LAB LTD (IN) 2025-07-23 EP disclosed
CN-119390623-A Racemization preparation method of apremilast and intermediate thereof 菏泽皓元医药科技有限公司 2025-02-07 CN disclosed
CN-118047701-A Preparation method of apremilast intermediate 浙江华义制药有限公司 2024-05-17 CN disclosed
CN-118047701-A Preparation method of apremilast intermediate 浙江华义制药有限公司 2024-05-17 CN disclosed
CN-107964016-B Thiophene derivatives 天津合美医药科技有限公司 2021-10-01 CN disclosed
CN-108059635-B Thiophene derivatives 天津合美医药科技有限公司 2021-10-01 CN disclosed
CN-110627694-B Method for recovering 3-ethoxy-4-methoxy-alpha- [ (methylsulfonyl) methyl ] -benzylamine 山东邹平大展新材料有限公司 2021-06-15 CN disclosed
WO-2013126495-A2 ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS CELGENE CORPORATION (US) 2013-08-29 WO disclosed
US-20130217919-A1 ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS CELGENE CORPORATION (US) 2013-08-22 US disclosed
US-20130217919-A1 ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS CELGENE CORPORATION (US) 2013-08-22 US disclosed
US-20130217919-A1 ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS CELGENE CORPORATION (US) 2013-08-22 US disclosed
US-8415485-B2 Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds CELGENE CORPORATION (US) 2013-04-09 US disclosed
US-20120107269-A1 THIOPHENE DERIVATIVES Tianjin Hemay Biotech Co., Ltd (CN) 2012-05-03 US disclosed
EP-2431371-A1 THIOPHENE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2012-03-21 EP disclosed
US-20110087033-A1 Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds AMGEN INC. 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110087033-A1 Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds PNMT, CYP2E1, CYP1A1 PDE4B 2125/4885PDE4A 2697/4885PDE4C 2410/4885
US-20180334429-A1 PROCESS FOR PREPARATION OF APREMILAST AND ITS INTERMEDIATES CMA1, MAST1, TPMT PDE4B 241/4885PDE4A 406/4885PDE4C 1276/4885
US-20120107269-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885
US-20130217919-A1 ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS STS, SULT2A1, CBS PDE4B 3924/4885PDE4A 4110/4885PDE4C 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.